Patents Represented by Attorney, Agent or Law Firm Jan Brunelle
  • Patent number: 6630297
    Abstract: Human Ect2 polypeptide, fragments and derivatives, along with vectors and host cells for expression and production of Ect2 polypeptide are provided. Various methods of screening for agents that modulate interaction of Ect2 with an Ect2 binding agent, including high throughput methods, are also provided.
    Type: Grant
    Filed: November 7, 2002
    Date of Patent: October 7, 2003
    Assignee: Exelixis, Inc.
    Inventors: Michael Martin Ollmann, Kevin Patrick Keegan, Thomas J. Stout, David Matthews, Alison Joly
  • Patent number: 6531644
    Abstract: Methods, transformation constructs, and transgenic animals for identifying anti-tumor agents and anti-tumor drug targets are described. The transformation constructs are used to generate transgenic animals that have altered expression of an oncogene or tumor suppressor gene in a target tissue that is dispensable for viability and reproduction. In some embodiments, the altered expression results in abnormal proliferation of the target tissue and normal proliferation in all other tissues. Anti-tumor drug targets can be identified by generating progeny of the transgenic animals that have mutations in various genes. Gene mutations that result in a specific reduction or killing of the target tissue are identified as possible anti-tumor drug targets and are further evaluated. Anti-tumor agents are identified that mimic the effect of the gene mutations that result in specific reduction of the target tissue.
    Type: Grant
    Filed: January 20, 2000
    Date of Patent: March 11, 2003
    Assignee: Exelixis, Inc.
    Inventors: Geoffrey Duyk, Felix D. Karim, Casey Kopczynski, Jenny Kopczynski
  • Patent number: 6489127
    Abstract: Methods, transformation constructs, and transgenic animals for identifying anti-tumor agents and anti-tumor drug targets are described. The transformation constructs are used to generate transgenic animals that have altered expression of an oncogene or tumor suppressor gene in a target tissue that is dispensable for viability and reproduction. In some embodiments, the altered expression results in abnormal proliferation of the target tissue and normal proliferation in all other tissues. Anti-tumor drug targets can be identified by generating progeny of the transgenic animals that have mutations in various genes. Gene mutations that result in a specific reduction or killing of the target tissue are identified as possible anti-tumor drug targets and are further evaluated. Anti-tumor agents are identified that mimic the effect of the gene mutations that result in specific reduction of the target tissue.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: December 3, 2002
    Assignee: Exelixis, Inc.
    Inventors: Geoffrey Duyk, Felix D. Karim